It is the cache of http://www.dovepress.com/update-on-the-clinical-use-of-the-low-molecular-weight-heparin-parnapa-a3574. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

Update on the clinical use of the low-molecular-weight heparin, parnap
skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14844

Update on the clinical use of the low-molecular-weight heparin, parnaparin



Review

(4439) Total Article Views


Authors: Giuseppe Camporese, Enrico Bernardi, Franco Noventa

Published Date September 2009 Volume 2009:5 Pages 819 - 831
DOI: http://dx.doi.org/10.2147/VHRM.S3430

Giuseppe Camporese1, Enrico Bernardi2, Franco Noventa3

1Unit of Angiology and 3Department of Clinical and Experimental Medicine, Clinical Epidemiology Group, University Hospital of Padua, Italy; 2Department of Emergency and Accident Medicine, Hospital of Conegliano Veneto, Italy

Abstract: Parnaparin is a low-molecular-weight heparin that has widely shown its efficacy and safety in prevention of venous thromboembolism, in the treatment of chronic venous disorders, and in the treatment of venous and arterial (stable and unstable angina, acute ST-segment elevation myocardial infarction) thrombosis. Parnaparin at the respective dosages of 3200, 4250, 6400, or 12800 IUaXa for a period ranging from 3 to 5 days to 6 months, is usually administered subcutaneously by means of once-daily regimen and is better tolerated than unfractionated heparin at the injection site. In the variety of commercially available low-molecular-weight heparins, parnaparin represents a useful therapeutic option, even though little evidence is available comparing the superiority or the equivalent efficacy and safety of parnaparin to that of the unfractionated heparin or placebo. This review summarizes the available literature on the use of parnaparin in different settings of cardiovascular diseases, including papers published during the past year and ongoing studies.

Keywords: low-molecular-weight heparin, heparin, parnaparin, acute coronary syndromes, venous thromboembolism




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:

  • ACC 2014

    We will attend the 2014 American College of Cardiology Scientific Session and Expo (ACC) on March 29-31, 2014. Stop by booth 3217 to talk with us.

  • Like us on Facebook

    Click the blue link above to become a part of our Facebook community.